



## The 65th ASH Annual Meeting Abstracts

## POSTER ABSTRACTS

**616.ACUTE MYELOID LEUKEMIAS: INVESTIGATIONAL THERAPIES, EXCLUDING TRANSPLANTATION AND CELLULAR IMMUNOTHERAPIES****A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia**

Junyuan Qi, MD<sup>1</sup>, Lin Song, MD<sup>2</sup>, Xudong Wei<sup>3</sup>, Zhimin Zhai, MD<sup>4</sup>, Anyou Wang, MD<sup>5</sup>, Daozi Jiang, MD<sup>6</sup>, Yang Liang, MD<sup>7</sup>, Fei Li<sup>8</sup>, Zhongxing Jiang<sup>9</sup>, Xuejun Zhang, MD<sup>10</sup>, Qunyi Guo<sup>11</sup>, Hongmei Jing, MD<sup>12</sup>, Yajing Xu, MD<sup>13</sup>, Xiangmin Tong, MD<sup>14</sup>, Jianxiang Wang, MD<sup>15</sup>

<sup>1</sup> State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematologic Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

<sup>2</sup> Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Peking Union College, Tianjin, China

<sup>3</sup> Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

<sup>4</sup> The Second Affiliated Hospital of Anhui Medical University, Hefei, China

<sup>5</sup> Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

<sup>6</sup> Department of Hematology, Hubei Provincial People's Hospital, Wuhan, China

<sup>7</sup> Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

<sup>8</sup> The First Affiliated Hospital of Nanchang University, Nanchang, China

<sup>9</sup> Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

<sup>10</sup> Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, China

<sup>11</sup> Department of Hematology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical College, Taizhou, China

<sup>12</sup> Peking University Third Hospital, Beijing, China

<sup>13</sup> Department of Hematology, Xiangya Hospital, Central South University, Changsha, China

<sup>14</sup> Department of Hematology, Hangzhou First People's Hospital, Hangzhou, China

<sup>15</sup> State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

**Abstract**

**Background:** The FMS-like tyrosine kinase 3 (FLT3) mutations occur in approximately 30% of acute myeloid leukemia (AML) patients, which are associated with worse survival and higher relapse risk. XY0206 is a novel oral FLT3 inhibitor with preclinical activity against FLT3 internal tandem duplication mutations (FLT3-ITD). The Phase I/II clinical trial with XY0206 (NCT04471064) is currently underway to explore the initial efficacy, safety and pharmacokinetic (PK) of XY0206 in patients with relapsed/refractory AML (R/R AML).

**Methods:** This open-label, multicenter, dose-escalation and dose-expansion Phase I/II trial enrolled subjects from August 2020 to September 2022 who were aged  $\geq 18$  years with R/R AML. Six dose-escalation or dose-expansion cohorts (12.5, 25, 37.5, 50, 62.5 mg per day, or 25 mg twice a day) were set up to explore the safety/tolerability and antileukemic activity of XY0206, and to determine the maximal tolerated dose (MTD) of XY0206. Safety and tolerability were assessed by monitoring dose-limiting toxicities (DLT), treatment-emergent adverse events (TEAE) and adverse drug reaction (ADR). Cohort expansion was based on safety and antileukemic activity.

**Results:** As of December 14, 2022, a total of 61 subjects were enrolled (37 with FLT3 mutation-positive). Demographics and baseline characteristics of patients are presented in Table 1. MTD of XY0206 was established as 50 mg when two of the three patients enrolled in the 62.5 mg dose-escalation cohort could not tolerate continuous medication. The 37.5 mg, 50 mg and

25 mg BID dose cohorts were further expanded. Antileukemic activity was assessed in the Full Analysis Set (FAS, n=61), with overall response rate (ORR) was 34.4% (n=21/61), composite complete remission (CRc) was 32.8% (n=20/61), complete remission (CR) was 6.6% (n=4/61) and CR with partial hematologic recovery (CRh) was 9.8% (n=6/61). Among the patients with FLT3 mutation-positive (FLT3<sup>mut+</sup>, n= 37), ORR was 48.6%(n=18/37), CRc was 45.9% (n=17/37), CR was 2.7% (n=1/37) and CRh was 16.2% (n=6/37). Among the patients with FLT3-ITD mutation (n=30), ORR was 56.7% (n=17/30), CRc was 53.3% (n=16/30), CR was 3.3% (n=1/30) and CRh was 20%( n=6/30). The 37.5 mg dose cohort as the target dose was further expanded to include FLT3<sup>mut+</sup> patients only. CRc in FLT3<sup>mut+</sup> patients ( n= 19 ) and FLT3-ITD mutation patients (n=16) was 57.9% (n=11/19) and 68.8% (n=11/16 ), CR was 5.3% (n=1/19) and 6.3% (n=1/16), CRh was 26.3% (n=5/19 ) and 31.3% (n=5/16), respectively. In terms of safety, the overall incidence and severity of TEAE/ADR in 61 subjects did not correlate with dose significantly. The most common grade 3 and above adverse events (≥ 50%) were leukopenia (65.6%), thrombocytopenia (63.9%), neutropenia (62.3%), anemia (52.5%) and hypokalemia (50.8%). The fatal adverse event was disease progression, which was mostly related to AML.

**Conclusion:** XY0206 is a novel FLT3 inhibitor that showed a good safety profile, a potent anti-leukemic activity and improved efficacy in patients with FLT3<sup>mut+</sup> R/R AML.

**Disclosures** No relevant conflicts of interest to declare.

Table 1: Baseline Demographics and Disease Characteristics.

	12.5mg (N=1) n(%)	25mg (N=4) n(%)	50mg (N=17) n(%)	37.5mg (N=21) n(%)	62.5mg (N=3) n(%)	25mg BID (N=15) n(%)	Total (N=61) n(%)
<b>Sex , n (%)</b>							
Male	0 (0.0%)	4 (100%)	7 (41.2%)	12 (57.1%)	3 ( 100%)	7 (46.7%)	33 (54.1%)
Female	1 (100%)	0 (0.0%)	10 (58.8%)	9 (42.9%)	0 (0.0%)	8 (53.3%)	28 (45.9%)
<b>Age (years)</b>							
Mean (SD)	39.0	50.8 (7.54)	50.0 (10.67)	49.9 (16.01)	47.7 (12.34)	51.1 (14.89)	50.0 (13.35)
Median (Min- Max)	39.0 (39, 39)	51.5 (42, 58)	53.0 (29, 64)	52.0 (20, 82)	51.0 (34, 58)	53.0 (20, 68)	52.0 (20, 82)
<b>FLT3 mutation type, n (%)</b>							
FLT3 <sup>mut+</sup>	0 (0.0%)	1 (25.0%)	11 (64.7%)	19 (90.5%)	0 (0.0%)	6 (40.0%)	37 (60.7%)
FLT3-ITD	0 (0.0%)	0 ( 0.0%)	9 (52.9%)	16 (76.2%)	0 (0.0%)	5 (33.3%)	30 (49.2%)

Table 2: Antileukemic Response to XY0206 in Patients With R/R AML.

Antileukemic Response	All Patients (n=61)	FLT3 <sup>mut+</sup> (n=37)	FLT3-ITD (n=30)	FLT3 <sup>mut+</sup> in 37.5 mg cohort (n=19)	FLT3-ITD in 37.5 mg cohort (n=16)
CR	6.6%	2.7%	3.3%	5.3%	6.3%
CRh	9.8%	16.2%	20%	26.3%	31.3%
CRc	32.8%	45.9%	53.3%	57.9%	68.8%
ORR	34.4%	48.6%	56.7%	57.9%	68.8%

Figure 1

<https://doi.org/10.1182/blood-2023-183088>

Downloaded from [http://ashpublications.net/blood/article-pdf/142/Supplement\\_1/2908/2190189/blood-9510-main.pdf](http://ashpublications.net/blood/article-pdf/142/Supplement_1/2908/2190189/blood-9510-main.pdf) by guest on 18 May 2024